Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
about
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancerRecent Advances in Stimuli-Responsive Release Function Drug Delivery Systems for Tumor TreatmentWeekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trialPhase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancerHistological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma.Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.Management of upper gastrointestinal cancers.Targeted therapies for gastric cancer: current status.S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.Towards a molecular approach to gastric cancer management.Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis.Pathological staging and therapy of oesophageal and gastric cancer.Docetaxel as salvage therapy in highly pretreated and drug resistant gastrointestinal carcinomas.Long-Term Survival of Gastric Adenocarcinoma without Therapy: Case Report.Efficacy and safety of oxaliplatin, 5-Fluorouracil, and folinic Acid combination chemotherapy as first-line treatment in metastatic or recurrent gastric cancerDocetaxel in advanced gastric cancer--review of the main clinical trials.Evolving role of chemoradiation in the adjuvant treatment of gastric cancer.A cost-benefit analysis of chemotherapy for gastric cancer.Palliative chemotherapy for advanced gastric cancer.Gastric and gastro-oesophageal cancer therapy.Chemotherapy for gastric cancer.A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancerMarimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation.A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.Capecitabine in the treatment of advanced gastric cancer.Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer.A phase II study of paclitaxel and cisplatin as salvage therapy for patients with advanced or metastatic gastric cancer.Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).Pre-operative chemotherapy for gastric cancer.
P2860
Q24649684-4D972E36-26A1-49C2-A0AA-E75B0390E3CAQ28078974-18B460CC-6A07-41C8-88D3-03C2AFEB0AFCQ33242985-84EDD018-20CF-43F4-B71C-BAE57D9780F3Q33361500-ED377315-D7B2-4585-AF70-18BFAF9F64B5Q33380002-A1A07F22-E8F8-40EB-BFCB-EAC94A5318A9Q33386875-22DD6681-6BF6-429B-A7B7-FF4E772DD970Q33402388-6E753044-02E6-44D2-AAF8-882F903F1265Q33403949-1F89C252-B56B-490E-94AB-3E4F60FD81B1Q33430940-36234ADA-76FC-48E7-ABDF-42E50FEE7E65Q33657791-E7285EF4-F1BF-4092-8829-F7D943999B9CQ33658636-3D8C643C-35B4-4F35-87AA-6A28CBC2119FQ33990928-97082577-6870-4111-92D5-2421D776A3FFQ34175118-4F5B68BA-6D73-498D-8C57-68F6E0CBE321Q34205672-AB04C884-1249-41BB-B7F7-27213C372136Q34257451-D1924837-A89E-4E67-A95D-63921B28707EQ34341290-4AAFA8F9-5CD6-4102-B725-1CF7A1B196C0Q34669648-63BE62D1-8A89-42B5-A531-AF9C12312381Q34852173-5269DD62-7D0A-4982-8374-E411796F2BCCQ35164696-F841194D-37C5-43CB-834F-E6F8440436DEQ35181089-A12B3076-3005-4284-B875-647CC98ECDC6Q35323682-72B299B6-9B81-47A9-87D8-8F3A267BEDE7Q35340883-0A08749C-9CC9-49EB-94B5-26CA61C53122Q35613504-56FB6EB8-9223-4C9F-8B8A-604632C9F5FEQ35843686-863F76B2-D630-4CAD-AF15-B6E141371946Q35906916-9B73BF71-A975-474F-94FE-AB1241AB5797Q35936039-164B4926-B093-4F56-B26B-E6BFFF98EEC3Q36327087-FBF4BEBA-ABE7-4F12-8A8C-CFDAB3EF241FQ36398226-8412EF90-86C5-4B19-BE8D-1C798E8BC8FFQ36614036-97900B6C-DD0A-4F4B-8A2D-15E06A81D557Q36615060-761CBD71-BDF5-4FEB-94F3-7B7625CFF0E9Q36616011-CD1F8C31-00B9-4A6A-9E45-72382E850EDEQ36642170-81B72A09-401E-4D3B-A478-F817406D84FFQ36644664-1824A65C-BEE1-4E52-87D6-CEB1738366B8Q36671309-044F8396-CEAC-4D32-9FB1-91E8135F5BB1Q36858273-EF2E0DCD-D588-488B-8EDC-4DABB4FA8210Q37136996-D76C3B36-9BCD-46A8-AA11-1B37F68DB913Q37336375-B0AD7C9B-5353-46AC-946C-36169703268FQ37336461-F10D5BD4-8D6F-4EE5-A001-403B392D1925Q37491365-135E20EB-F95C-4779-B5ED-EE02C5AEE044Q37636574-220CE3EE-5D58-414E-AC55-A289D318DD60
P2860
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Long-term survival after epiru ...... results of a randomized trial.
@en
Long-term survival after epiru ...... results of a randomized trial.
@nl
type
label
Long-term survival after epiru ...... results of a randomized trial.
@en
Long-term survival after epiru ...... results of a randomized trial.
@nl
prefLabel
Long-term survival after epiru ...... results of a randomized trial.
@en
Long-term survival after epiru ...... results of a randomized trial.
@nl
P2093
P2860
P356
P1476
Long-term survival after epiru ...... results of a randomized trial.
@en
P2093
Nicolson M
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690350
P407
P577
1999-04-01T00:00:00Z